← Back to Search

Unknown

AZD7503 for Safety

Phase 1
Waitlist Available
Research Sponsored by AstraZeneca
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up (pre-dose and post-dose) days 1 to 4
Awards & highlights

Study Summary

This trial will study the effects of a new drug, given as a shot, in healthy people. They will look at how safe it is and how it affects the body.

Eligible Conditions
  • Safety
  • Tolerability
  • Pharmacokinetics
  • Healthy Subjects

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~(pre-dose and post-dose) days 1 to 4 and final fu visit (week 10 post last dose) or et (assessed up to 14 weeks)
This trial's timeline: 3 weeks for screening, Varies for treatment, and (pre-dose and post-dose) days 1 to 4 and final fu visit (week 10 post last dose) or et (assessed up to 14 weeks) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of participants with Adverse Events (AEs)
Secondary outcome measures
Apparent total body clearance of drug from plasma after extravascular administration (CL/F) of AZD7503
Apparent volume of distribution at steady state following extravascular administration (Vz/F) of AZD7503
Area under plasma concentration time-curve from zero to infinity (AUCinf) of AZD7503
+11 more

Trial Design

12Treatment groups
Experimental Treatment
Placebo Group
Group I: Japanese Cohort 2: AZD7503 dose 4Experimental Treatment1 Intervention
Randomised healthy Japanese participants will receive a single dose 4 of AZD7503.
Group II: Japanese Cohort 1: AZD7503 dose 3Experimental Treatment1 Intervention
Randomised healthy Japanese participants will receive a single dose 3 of AZD7503.
Group III: Cohort 6: AZD7503 dose YExperimental Treatment1 Intervention
Randomised healthy participants will receive a single dose Y of AZD7503.
Group IV: Cohort 5 : AZD7503 dose XExperimental Treatment1 Intervention
Randomised healthy participants will receive a single dose X of AZD7503.
Group V: Cohort 4: AZD7503 dose 4Experimental Treatment1 Intervention
Randomised healthy participants will receive a single dose 4 of AZD7503.
Group VI: Cohort 3: AZD7503 dose 3Experimental Treatment1 Intervention
Randomised healthy participants will receive a single dose 3 of AZD7503.
Group VII: Cohort 2: AZD7503 dose 2Experimental Treatment1 Intervention
Randomised healthy participants will receive a single dose 2 of AZD7503.
Group VIII: Cohort 1: AZD7503 dose 1Experimental Treatment1 Intervention
Randomised healthy participants will receive a single dose 1 of AZD7503.
Group IX: Chinese Cohort: AZD7503 dose 4Experimental Treatment1 Intervention
Randomised healthy Chinese participants will receive a single dose 4 of AZD7503.
Group X: Pooled Placebo for AZD7503 (Cohorts 1 to 6)Placebo Group1 Intervention
Randomised healthy participants will receive placebo.
Group XI: Placebo (Japanese Cohorts)Placebo Group1 Intervention
Randomised healthy Japanese participants will receive placebo.
Group XII: Placebo (Chinese Cohort)Placebo Group1 Intervention
Randomised healthy Chinese participants will receive placebo.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AZD7503
2021
Completed Phase 1
~60

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

AstraZenecaLead Sponsor
4,265 Previous Clinical Trials
288,605,226 Total Patients Enrolled
11 Trials studying Safety
685 Patients Enrolled for Safety

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7503 in Healthy Participants
2021. "A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7503 in Healthy Participants". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05143905.
~17 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top